Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial, OncoTargets and Therapy, March 2016, Dove Medical Press,
DOI: 10.2147/ott.s89755.
You can read the full text:

Read
Open access logo

Contributors

The following have contributed to this page